Experience with Optivate®, a new high purity concentrate of factor VIII with von Willebrand factor, in patients undergoing surgery

The efficacy and safety of Optivate® was assessed in 23 surgical operations, orthopaedic (12) including 5 revision arthroplasties, ophthalmic (1), ENT (1), dental (6), liver biopsy (2), and removal of portacath (1) on 15 teenagers and adults with severe haemophilia A. The preoperative dose was calcu...

Full description

Saved in:
Bibliographic Details
Published in:Haemophilia : the official journal of the World Federation of Hemophilia 2011-05, Vol.17 (3), p.428-432
Main Authors: HAY, C. R. M., HELLMANN, A., DMOSZYNSKA, A., BAGLIN, T., O'SHAUNESSEY, D., MAKRIS, M., SHAIKH-ZAIDI, R., DASH, C. H.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Blood Loss, Surgical - prevention & control
Drug Combinations
efficacy
factor VIII
Factor VIII - therapeutic use
haemophilia A
Hemophilia A - drug therapy
Hemophilia A - surgery
Hemostasis, Surgical - methods
Hemostatics - therapeutic use
Humans
Middle Aged
Perioperative Care - methods
Preoperative Care - methods
safety
surgery
von Willebrand Factor - therapeutic use
Young Adult
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The efficacy and safety of Optivate® was assessed in 23 surgical operations, orthopaedic (12) including 5 revision arthroplasties, ophthalmic (1), ENT (1), dental (6), liver biopsy (2), and removal of portacath (1) on 15 teenagers and adults with severe haemophilia A. The preoperative dose was calculated to raise the FVIII concentration to 100 IU dL−1. Subsequent doses were targeted to maintain at least 50 IU dL−1. There were 11 major and 12 minor operations categorized as receiving intensive replacement therapy for ≥5 days or
ISSN:1351-8216
1365-2516
DOI:10.1111/j.1365-2516.2010.02441.x